# Mirum Pharmaceuticals share price today (Mirum Pharmaceuticals, Inc., MIRM)

> Mirum Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. MIRM · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/mirm

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $93.54 (+37.3% in a year)
- Revenue (Jun 2026): $176 M (+37.9% on a year ago)
- Profit (Jun 2026): −$67.2 M
- Operating margin: −14.8% (−10.9 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Mirum Pharmaceuticals share price today? Mirum Pharmaceuticals, Inc.'s share price was $93.54 at the close on 5 November 2026. It has been moving sideways for 8 weeks. That is 5.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $65 and $126, and at that close it sat 47% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 7.3 years the share price moved +593% while the S&P 500 moved +147%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Mirum Pharmaceuticals pay? Mirum Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Mirum Pharmaceuticals on? Mirum Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Mirum Pharmaceuticals profitable? Mirum Pharmaceuticals, Inc. posted a net loss of $67.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $23.4 M. That loss is 38.1% of the quarter's revenue. The same quarter a year earlier lost $5.9 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Mirum Pharmaceuticals make, and is it growing? Mirum Pharmaceuticals, Inc. reported $176 M of revenue in the Jun 2026 quarter, +37.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 128.5% a year on average. The last full year, FY25, came in at $521 M. The last four reported quarters add to $618 M. FY25 revenue was $521 M, +54.7% on the year before. Recent pace: the last four quarters grew +44.6% on average, against 128.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +44.0%, against +52.9% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Mirum Pharmaceuticals keep? Mirum Pharmaceuticals, Inc.'s operating margin was −14.8% in the Jun 2026 quarter, 10.9 percentage points lower than the same quarter a year ago. Across 5 years it has been between −906.1% and −4.2%. The latest quarter is within that range. Why the margin moved: operating margin changed −10.9 percentage points on the year while gross margin changed +1.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Mirum Pharmaceuticals' profit turning into cash? Mirum Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $55.8 M of operating cash against −$23.4 M of profit. After $954 K of spending on assets, $54.9 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Mirum Pharmaceuticals' cash go? Mirum Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.1 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Mirum Pharmaceuticals' P/E ratio, and how does it compare with its own history? Mirum Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Mirum Pharmaceuticals, Inc. at 11.7× its FY25 revenue of $521 M. The P/E comes back here once profit turns positive. ## Is the Mirum Pharmaceuticals business getting better or worse? Mirum Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Mirum Pharmaceuticals earn on its capital? Mirum Pharmaceuticals, Inc. earned a ROE of −7% in FY25. That is up from a low of −96% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −1,529%, a number that says nothing useful about the business. It comes from a −4.5% net margin and 0.62× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −4.5% net margin × 0.62× asset turnover × 2.68× leverage (assets divided by equity) ≈ −7.5% on equity. The margin does its share; borrowing is a big part of it. ## Does Mirum Pharmaceuticals have too much debt? Mirum Pharmaceuticals, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.02 in FY21 to 1.02 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Mirum Pharmaceuticals shareholding pattern? 11.8% of Mirum Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Mirum Pharmaceuticals from balance-sheet trouble? For Mirum Pharmaceuticals, Inc., the Z-score is 1.44. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.44 is inside the danger zone, so the balance sheet is a real risk. ## How does Mirum Pharmaceuticals rank in its industry? There is no score against its industry: Mirum Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Mirum Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Mirum Pharmaceuticals in size? Mirum Pharmaceuticals is the 39th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Rhythm Pharmaceuticals, Inc., Axsome Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Just below it: Ligand Pharmaceuticals Incorporated, CG Oncology, Inc. and Scholar Rock Holding Corporation. ### Biotechnology companies close in size

1. [Rhythm Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rytm) $7.3 billion
2. [Axsome Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/axsm) $6.8 billion
3. [Ionis Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/ions) $6.4 billion
4. Mirum Pharmaceuticals, Inc. $6.1 billion
5. [Ligand Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/lgnd) $6 billion
6. [CG Oncology, Inc.](https://www.sectoralpha.in/us/stocks/cgon) $5.7 billion
7. [Scholar Rock Holding Corporation](https://www.sectoralpha.in/us/stocks/srrk) $5.5 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Fluor Corporation](https://www.sectoralpha.in/us/stocks/flr) $6.4 billion · Engineering & Construction
2. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) $6.4 billion · Medical Instruments & Supplies
3. Mirum Pharmaceuticals, Inc. $6.3 billion
4. [Ligand Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/lgnd) $6.3 billion · Biotechnology
5. [Matson, Inc.](https://www.sectoralpha.in/us/stocks/matx) $6.3 billion · Marine Shipping

## What else do people ask about Mirum Pharmaceuticals? ### What were Mirum Pharmaceuticals's latest quarterly results? Mirum Pharmaceuticals, Inc. reported revenue of $176 M and a net loss of $67.2 M for the Jun 2026 quarter. Earnings per share were −$1.06. The operating margin was −14.8%, 10.9 percentage points lower than a year earlier (as of 5 November 2026). ### What is Mirum Pharmaceuticals's market cap? Mirum Pharmaceuticals, Inc.'s market capitalisation is $6.1 B at a stock price of $93.54. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Mirum Pharmaceuticals performing? Mirum Pharmaceuticals, Inc.'s share price has been moving sideways for 8 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Mirum Pharmaceuticals's stock price go up? This page does not forecast Mirum Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $93.54, and it has been moving sideways for 8 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Mirum Pharmaceuticals have too much debt? Yes, Mirum Pharmaceuticals, Inc. has a lot of debt: its debt is 1.34× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is Mirum Pharmaceuticals in its business cycle? Mirum Pharmaceuticals, Inc.'s FY25 operating margin was −4.2%, against a 5-year range of −906.1% to −4.2%: the middle of its own range, neither a peak nor a low. The latest quarter was −14.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Mirum Pharmaceuticals story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Mirum Pharmaceuticals a stock worth studying right now? What the numbers show: Mirum Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.